7794 results for "canc*"

in 9.48 milliseconds.

• Data access committee for study: "Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer"

  This is the Data Access committee that regulates access to the sequence data for the study: "Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer".

  Dac EGAC50000000787

• Wellcome LEAP TNBC cohort raw sequencing data

  This study contains controlled-access raw sequencing data from the retrospective Wellcome LEAP triple-negative breast cancer cohort. The data include human patient-derived single-nucleus RNA-seq and 10x Visium spatial transcriptomics generated from pre- and post-treatment tumour samples. The first dataset linked to this study supports the Victori et al. Cell Reports Medicine manuscript and includes raw FASTQ files from the relevant sequencing runs. Because some snRNA-seq libraries were generated from multiplexed pools, some raw FASTQ files may include additional co-multiplexed LEAP samples beyond those directly analysed in that manuscript. Access is controlled through the appropriate LEAP Data Access Committee and policy.

  Study EGAS50000001956

• Wellcome LEAP TNBC Data Access Committee

  Data Access Committee for controlled-access human patient-derived sequencing data from the Wellcome LEAP triple-negative breast cancer study

  Dac EGAC50000001072

• Synthetic longitudinal breast cancer whole-genome sequencing dataset

  This study contains fully simulated longitudinal whole-genome sequencing data for one synthetic female breast cancer patient. It includes one matched-normal paired-end sample generated at a nominal depth of 30x and three longitudinal tumour samples generated at a nominal depth of 60x.

  Study EGAS50000001932

• Non-invasive anal (pre)cancer dataset DAC

  Dac EGAC00001003635

• Synthetic longitudinal breast cancer whole-genome sequencing dataset

  Synthetic longitudinal breast cancer whole-genome sequencing dataset generated at the Barcelona Supercomputing Center (BSC). This study contains fully simulated longitudinal whole-genome sequencing data for one synthetic female breast cancer patient. It includes one matched-normal paired-end sample generated at a nominal depth of 30× and three longitudinal tumour samples generated at a nominal depth of 60×.

  Dataset EGAD50000002802

• Serafini et al., Nuclear localization of the glutaminyl-tRNA synthetase QARS reveals its role in DNA damage response in ovarian cancer

  Uncovering novel mechanisms controlling DNA damage response (DDR) is essential to better understand the molecular features of high-grade serous ovarian cancers (HGSOC), which remain a clinical challenge. Here, we demonstrate that the glutaminyl-tRNA-synthetase QARS is a new key player in DDR. We show that QARS is regulated at translational level by the MAPK pathway in HGSOC and controls homologous recombination (HR) through a translation-independent mechanism. Analyses combining RNA sequencing, immunohistochemistry, proteomic data and functional assays from HGSOC patient cohorts and relevant cellular models reveal that QARS promotes DNA repair via the HR pathway. Interestingly, we uncover that QARS is located in the nucleus and is enriched at chromatin upon DNA damage. Nuclear QARS controls HR by interacting with the nuclear autoantigen SP100, a major component of PML-nuclear bodies (PML-NB), that are regulatory hubs for DNA repair proteins. Our data highlight novel nuclear functions and mechanisms for QARS involving SP100, PML-NB and MRE11 that enhance HR in HGSOC.

  Study EGAS50000001968

• Division of Molecular Oncology, National Cancer Center Research Institute Data Access Committee

  Dac EGAC00001001272

• RAIDs cervical cancer project

  The RAIDS project, launched by the Curie Institute in 2013, aims to molecularly characterize cervical cancer (CC) and improve patient risk stratification. As part of the Bio-RAIDS study (NCT02428842), next-generation sequencing was performed on tumor samples (whole-exome sequencing, shallow whole-genome sequencing and RNA-sequencing) identified frequent alterations, including PIK3CA (30%) and prognostic biomarkers like TERT, linked to poor progression-free survival. Over 50 clinically targetable mutations were found, offering new therapeutic opportunities. Transcriptomic analysis also linked specific genes and pathways to prognosis and tumor necrosis.

  Study EGAS50000001012

• RAIDs transcriptomic dataset

  Here, we describe molecular alterations in 270 cervical cancer patients using 270 tumor frozen samples using RNA-sequencing technology. Tumor samples were obtained from cervical tumor tissue collected at diagnosis. FASTQ files are deposited in the dataset.

  Dataset EGAD50000001479